Search
for
Sort by
Research 181–210 of 1000+
- Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Alopecia Totalis/Universalis
- Role of Cytotoxic T Cells in Chronic Alopecia Areata
- Alopecia Areata: Current Treatments and New Directions
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Eyebrow and Eyelash Alopecia: A Clinical Review
- Immune therapies for alopecia areata: evidence and new perspectives
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Nonscarring alopecia after temporal lifting technique with dermal fillers
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Polynucleotides Versus Platelet-Rich Plasma for Androgenetic Alopecia: A Case Series
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Androgenetic alopecia – Update 2022
- Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis
- Alopecia areata following COVID-19 vaccine: a systematic review
- Alopecia universalis after injection of messenger RNA COVID-19 vaccine. A case report
- Alopecia Areata
- Alopecia Areata: An Updated Review for 2023
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- JAK Inhibitors for Treatment of Alopecia Areata
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- Role of janus kinase inhibitors in the treatment of alopecia areata